Oncotelic Therapeutics (OTCQB: OTLC) announced that its subsidiary, Sapu Nano, will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation, scheduled to take place in 2026, will highlight findings on tissue concentration-driven effects and organ-specific outcomes that go beyond traditional plasma pharmacokinetics. This research underscores the importance of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
The significance of this announcement lies in the potential to enhance the therapeutic index of everolimus, a drug used in oncology and other indications, by understanding how its distribution within tissues affects safety and efficacy. By moving beyond plasma concentration measurements, Sapu Nano's research could lead to more precise dosing regimens and reduced side effects. The data being presented at SOT 2026 is expected to provide insights into how nanoparticle formulations can alter drug biodistribution, potentially unlocking new clinical applications for established therapeutics.
Oncotelic Therapeutics, through its wholly owned subsidiary Sapu Nano, is focused on developing next-generation nanomedicine platforms to improve drug delivery. The company has a special emphasis on rare pediatric cancers, with rare pediatric designations for Diffuse Intrinsic Pontine Glioma (DIPG) through OT-101, melanoma through CA4P, and Acute Myeloid Leukemia (AML) through OXi 4503. Additionally, Oncotelic acquired PointR Data Inc. in 2019 to build an AI-driven biotechnology company and acquired AL-101 in 2021 for intranasal delivery of apomorphine, targeting Parkinson's disease and other conditions.
The presentation at SOT 2026 represents a key step in validating Sapu Nano's approach to drug delivery, which aims to enhance therapeutic outcomes by optimizing tissue-level pharmacokinetics. For more information on Oncotelic Therapeutics and its subsidiaries, visit the company's newsroom at https://ibn.fm/OTLC. The full press release regarding this announcement can be accessed at https://ibn.fm/kZzE3.
